WEST VANCOUVER

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

Retrieved on: 
Giovedì, Maggio 30, 2024
CTA, MPH, Patient, Tislelizumab, Investigational New Drug, FDA, IND, BCT, Safety, PD-1, Cancer, Immunotherapy, Institutional review board, TSX, Quality of life, IRB, Pharmaceutical industry

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab , in advanced metastatic breast cancer.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab , in advanced metastatic breast cancer.
  • “Advancing Bria-OTS™ as our second novel immunotherapy candidate into the clinic is a significant milestone for BriaCell.
  • We believe personalization through our Bria-OTS™ immunotherapy platform will produce more potent and long-lasting responses than previously observed, with potential synergistic effects with the immune check point inhibitor,” stated Dr. William V. Williams, BriaCell’s President & CEO.
  • Additionally, we expect the preferred safety profile of our personalized immunotherapy, Bria-OTS™, to improve the quality of life and add months and even years to the lives of these heavily pretreated patients, a distinctive combination of benefits in late-stage cancer care.”

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Retrieved on: 
Martedì, Maggio 28, 2024
BeiGene, Patient, Tislelizumab, Survival, Clinical trial, Therapy, Safety, Breast cancer, Prostate, Spacecraft, Cancer, CNS, Immunotherapy, TSX, Central nervous system, Pharmaceutical industry

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.

Key Points: 
  • Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.
  • “We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers,” stated Dr. William V. Williams, BriaCell’s President & CEO.
  • “In our randomized Phase 2 and other trials of Bria-IMT™, BriaCell immunotherapy has shown survival and clinical benefit in patients with central nervous system (CNS) metastases and after progression on antibody drug conjugates (ADCs).
  • BriaCell also plans to evaluate Bria-OTS™ in prostate and other cancers.

Lancaster Resources Welcomes Three Highly Experienced Industry Experts to Its Advisory Board

Retrieved on: 
Lunedì, Maggio 27, 2024
Lithium, Strategic management, Gold, Corporate governance, LCR, Corporate communication, Can-Am, Corporation, A&D, Capital market, Research, Constructor, Knowledge, Water

VANCOUVER, British Columbia, May 27, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF0) (“Lancaster”), a critical mineral exploration company, is delighted to welcome three distinguished professionals to its advisory board: Greg Foofat, Patrick Laperrière, and Jay Swartzentruber.

Key Points: 
  • Jay Swartzentruber - As Director at Canam Metals, Mr. Swartzentruber is set to produce lithium and gold with exceptionally low production costs.
  • VANCOUVER, British Columbia, May 27, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF0) (“Lancaster”), a critical mineral exploration company, is delighted to welcome three distinguished professionals to its advisory board: Greg Foofat, Patrick Laperrière, and Jay Swartzentruber.
  • Greg Foofat brings over 20 years of robust experience in Investor Relations, Corporate Communications, Capital Markets, Corporate Governance, and Corporate Strategy.
  • Greg is an invaluable addition to our advisory board, bringing a wealth of knowledge and strategic insight.

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

Retrieved on: 
Venerdì, Maggio 24, 2024
MPH, Patient, Doctor of Philosophy, Prognosis, Mayo Clinic, Clinical trial, University, Therapy, BCT, Safety, University of Washington, FACP, ADC, Principal investigator, Spacecraft, Wilfrid Sellars, ASCO, Abstract, Society, TSX, Annual general meeting, Pharmaceutical industry

The abstracts for these presentations are now available at https://conferences.asco.org/am/abstracts .

Key Points: 
  • The abstracts for these presentations are now available at https://conferences.asco.org/am/abstracts .
  • “Patients with heavily pretreated metastatic breast cancer that have developed resistance to antibody drug conjugates (ADC) face a very poor prognosis.
  • “With 4 published abstracts and an oral presentation, we expect this year’s ASCO Annual Meeting to be a very important event for BriaCell,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer.
  • 5/6 (83%) of evaluable patients (one inevaluable) with intracranial lesions treated with Bria-IMT™ in all BriaCell studies had intracranial responses, including complete and partial responses

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Retrieved on: 
Venerdì, Maggio 17, 2024
Offering, Patent, Exercise, BCT, Therapy, Telephone, Sale, Minority, Form, Prospectus, Research, Multilateral, Global Partners, TSX, Contract research organization, Madison Avenue, Security (finance)

This Offering was made pursuant to an effective shelf registration statement on Form S-3 (File No.

Key Points: 
  • This Offering was made pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The Offering was also conducted on a private placement basis in Canada in reliance upon available exemptions from the prospectus requirements of applicable Canadian securities laws.
  • The Company advises that a director of the Company participated in the Offering.
  • The Company deemed this circumstance reasonable in order to complete the Offering in an expeditious manner.

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

Retrieved on: 
Mercoledì, Maggio 15, 2024
Offering, Patent, Exercise, BCT, Therapy, Telephone, Sale, Minority, Form, Prospectus, Research, Multilateral, TSX, Madison Avenue, Life insurance

The closing of the Offering is expected to take place on or about May 17, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the Offering is expected to take place on or about May 17, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the Offering will be approximately $5.0 million before deducting placement agent fees and other estimated Offering expenses payable by the Company.
  • This Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The Company deems this circumstance reasonable in order to complete the issuance of the Offering in an expeditious manner.

Lancaster Resources Receives BLM Drilling Approval for Alkali Flat Lithium Brine Project

Retrieved on: 
Mercoledì, Maggio 15, 2024
Lithium, LCR, USD, News, MMD, Letter, KGRA, National instrument, Safety, Dry lake, BLM, Lightning, Environment

VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF0) (“Lancaster”) announces that the United States Department of the Interior Bureau of Land Management (“BLM”) has provided Lancaster with approval for the Plan of Operations regarding the Alkali Flat Lithium Brine Phase 1 drill program.

Key Points: 
  • VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF0) (“Lancaster”) announces that the United States Department of the Interior Bureau of Land Management (“BLM”) has provided Lancaster with approval for the Plan of Operations regarding the Alkali Flat Lithium Brine Phase 1 drill program.
  • "We are rapidly progressing to drilling our maiden exploration well at Alkali Flat and showing the significant potential lithium brine deposit in the subsurface aquifers identified by our 2023 geophysics program."
  • In addition to the approval are conditions for access, safety, and protecting the environment that the BLM and Lancaster have worked very closely on.
  • The Alkali Flat Lithium Project targets a closed-basin brine deposit in a playa lake setting.

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024
Wilfrid Sellars, University, Mayo Clinic, Weill Cornell Medicine, University of Miami, Poster, BCT, MD, TSX, Principal investigator, Doctor of Philosophy, Spacecraft, UPMC, McCormick Place, DRS, ASCO, Cornell University, ADC, Patient, Society, Annual general meeting, Therapy, Partner, Pharmaceutical industry

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD

Key Points: 
  • Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
    Two poster presentations include Drs.
  • Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, will be giving the presentation.
  • BriaCell will also have two poster presentations.
  • The first poster will describe the Company’s ongoing pivotal Phase 3 registrational study in advanced metastatic breast cancer.

Our Collective Advantage: Hundreds of Indigenous, Government and Industry Leaders convene on Bay Street

Retrieved on: 
Lunedì, Aprile 22, 2024
First Nations, Chairperson, Sheraton Centre, Heart, Knowledge

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Today marks the commencement of the First Nations Major Projects Coalition’s (FNMPC) highly anticipated seventh annual conference in Toronto at the Sheraton Centre.

Key Points: 
  • TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Today marks the commencement of the First Nations Major Projects Coalition’s (FNMPC) highly anticipated seventh annual conference in Toronto at the Sheraton Centre.
  • Welcoming an esteemed gathering of financial sector and business leaders, government officials and First Nations representatives, the conference, titled Our Collective Advantage: Indigenous Consent (“OCA”), promises to be a visionary platform for dialogue, collaboration, and the forging of strategic partnerships.
  • “The opening of the conference in Toronto for the first time today marks a pivotal moment in our collective efforts toward economic collaboration,” said Chief Sharleen Gale, Chair of the Board, First Nations Major Projects Coalition.
  • “The dialogue at this year’s conference will be instrumental in shaping a more inclusive and resilient economy where First Nations can be true partners in economic prosperity.”

Media Advisory: First Nations Major Projects Coalition to Host Canada’s Largest Indigenous-Led Conference in Toronto Next Week

Retrieved on: 
Mercoledì, Aprile 17, 2024
Policy, First Nations, Chairperson, Canada Infrastructure Bank, Assembly of First Nations, Private sector, Government, Knowledge, Mining

TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- The First Nations Major Projects Coalition (FNMPC) will host its seventh annual conference in Toronto April 22-23, 2024, marking the first time the premiere event is being held in the city.

Key Points: 
  • TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- The First Nations Major Projects Coalition (FNMPC) will host its seventh annual conference in Toronto April 22-23, 2024, marking the first time the premiere event is being held in the city.
  • The two-day conference, titled, Our Collective Advantage: Indigenous Consent (“OCA”), will provide a platform for financial sector and business leaders, government officials and First Nations leaders to engage in dialogue, collaborate and forge strategic partnerships.
  • “Bringing our annual conference in Toronto for the first time marks a significant milestone for the First Nations Major Projects Coalition as we unite diverse voices from the private sector, government and First Nations in Canada’s financial centre to cultivate crucial partnerships and drive progress toward economic reconciliation,” said Chief Sharleen Gale, Chair of the Board, First Nations Major Projects Coalition.
  • Hillary Thatcher (Métis), Managing Director, Investments, Indigenous and Northern Infrastructure, Canada Infrastructure Bank
    National Chief Cindy Woodhouse Nepinak, (Pinaymootang Nation), Assembly Of First Nations